

**REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)**

in re Application of \_\_\_\_\_

Application Number

09/920,215

Filed

8-1-01

Art Unit

Examiner

Paper No. \_\_\_\_\_

Assistant Commissioner for Patents  
Washington, DC 20231

1. ☐ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:United States Patent Application Publication No. 2002/0099092, page \_\_\_\_\_, line \_\_\_\_\_,

United States Patent Number \_\_\_\_\_, column \_\_\_\_\_, line \_\_\_\_\_, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. \_\_\_\_\_, paper No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Signature

Ivan Chau

Typed or printed name

6-23-03

Date

FOR PTO USE ONLY

Approved by: \_\_\_\_\_

(initials)


Unit: \_\_\_\_\_



US 20020099092A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2002/0099092 A1**  
**Blakemore et al.** (43) **Pub. Date: Jul. 25, 2002**(54) **ALKYL AMINO ACID DERIVATIVES  
USEFUL AS PHARMACEUTICAL AGENTS**(76) **Inventors: David Clive Blakemore,**  
Cambridgeshire (GB); **Justin Stephen**  
**Bryans, Balsham (GB); Sophie**  
**Caroline Williams, Cambridge (GB)**Correspondence Address:  
**Charles W. Ashbrook**  
**Warner-Lambert Company**  
**2800 Plymouth Road**  
**Ann Arbor, MI 48105 (US)**(21) **Appl. No.: 09/920,215**(22) **Filed: Aug. 1, 2001**(30) **Foreign Application Priority Data**

Aug. 1, 2000 (GB) ..... 0018828.4

**Publication Classification**(51) **Int. Cl.<sup>7</sup> ..... A61K 31/198; A61K 31/195;**  
**A61K 31/22**(52) **U.S. Cl. .... 514/551; 514/561; 560/38;**  
**560/155; 562/443**(57) **ABSTRACT**GABA-related pro-drugs of the formula (III) are provided  
that when administered to humans or other mammals pro-  
vide an increased duration of active compound in the plasmacompared to compounds of corresponding structure in which  
labile groups are not present. The compounds are of the  
formula (III)

(III)

In the above formula:

P represents hydrogen or methyl;

Q represents a labile amine- or amide-forming organic  
group that becomes removed in the human or animal  
body;R<sup>1</sup> represents straight or branched C<sub>2</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub>  
cycloalkyl or phenyl;R<sup>2</sup> represents hydrogen or methyl; andR<sup>3</sup> represents hydrogen, methyl or carboxyl; andR<sup>4</sup> represents hydrogen or a labile ester-forming group  
selected from substituted and unsubstituted C<sub>1</sub>-C<sub>6</sub>  
alkyl, benzyl and phenyl groups that become  
removed in the human or animal body. In the above  
formula when R<sup>1</sup> is phenyl, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are not  
simultaneously hydrogen. Pharmaceutically accept-  
able salts of any salt-forming compound within the  
above class are also included. The compounds may  
be used to treat a range of neurological conditions,  
e.g. epilepsy and pain.